At a glance
ClinicalIndex Comparison RecordN/ACompleted· 173 enrolled
Drug / intervention
Eclipse novel CPAP mask +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Trial to Compare Effectiveness of DreamPort-Eclipse to a Traditional Nasal Mask
In Brief
A clinical study evaluating Eclipse novel CPAP mask and ResMed P-10 mask for Obstructive Sleep Apnea. Completed, enrolled 173 participants across 1 site.
Detailed Summary
The Randomized Controlled Trial of Bleep DreamPort-Eclipse Study is a two-arm, randomized, prospective, non-blinded study to assess the effectiveness of the novel CPAP human interface design to improve leak, AHI, and pressure compared to a traditional nasal mask.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
202420252026
Enrollment StartApr 2023
First PostedApr 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedApr 19, 2023
Enrollment StartApr 17, 2023
Primary CompletionDec 29, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.2 years ago
Interventions
Eclipse novel CPAP maskdevice
Participants will wear the mask for 6 hours a night for 60 days.
ResMed P-10 maskdevice
Participants will wear the mask for 6 hours a night for 60 days.